These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 33771555)

  • 21. Leishmania vaccines: progress and problems.
    Kedzierski L; Zhu Y; Handman E
    Parasitology; 2006; 133 Suppl():S87-112. PubMed ID: 17274851
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Understanding the immune responses involved in mediating protection or immunopathology during leishmaniasis.
    Pacheco-Fernandez T; Volpedo G; Verma C; Satoskar AR
    Biochem Soc Trans; 2021 Feb; 49(1):297-311. PubMed ID: 33449103
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Immunopathology of American tegumentary leishmaniasis].
    Castés M; Tapia FJ
    Acta Cient Venez; 1998; 49(1):42-56. PubMed ID: 10205916
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunotherapy, immunochemotherapy and chemotherapy for American cutaneous leishmaniasis treatment.
    Mayrink W; Botelho AC; Magalhães PA; Batista SM; Lima Ade O; Genaro O; Costa CA; Melo MN; Michalick MS; Williams P; Dias M; Caiaffa WT; Nascimento Ed; Machado-Coelho GL
    Rev Soc Bras Med Trop; 2006; 39(1):14-21. PubMed ID: 16501760
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Second-generation vaccines against leishmaniasis.
    Coler RN; Reed SG
    Trends Parasitol; 2005 May; 21(5):244-9. PubMed ID: 15837614
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Leishmaniasis: clinical syndromes and treatment.
    McGwire BS; Satoskar AR
    QJM; 2014 Jan; 107(1):7-14. PubMed ID: 23744570
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Imaging host-Leishmania interactions: significance in visceral leishmaniasis.
    Forestier CL
    Parasite Immunol; 2013; 35(9-10):256-66. PubMed ID: 23772814
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunotherapeutic Potential of Interleukin-32 and Trained Immunity for Leishmaniasis Treatment.
    Teufel LU; Joosten LAB; Dos Santos JC
    Trends Parasitol; 2021 Feb; 37(2):130-141. PubMed ID: 33082090
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotherapy versus chemotherapy in localised cutaneous leishmaniasis.
    Convit J; Castellanos PL; Rondon A; Pinardi ME; Ulrich M; Castes M; Bloom B; Garcia L
    Lancet; 1987 Feb; 1(8530):401-5. PubMed ID: 2880213
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A historical review of the role of cytokines involved in leishmaniasis.
    Mirzaei A; Maleki M; Masoumi E; Maspi N
    Cytokine; 2021 Sep; 145():155297. PubMed ID: 32972825
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Possibilities and challenges for developing a successful vaccine for leishmaniasis.
    Srivastava S; Shankar P; Mishra J; Singh S
    Parasit Vectors; 2016 May; 9(1):277. PubMed ID: 27175732
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Translating Observations From Leishmanization Into Non-Living Vaccines: The Potential of Dendritic Cell-Based Vaccination Strategies Against
    Seyed N; Peters NC; Rafati S
    Front Immunol; 2018; 9():1227. PubMed ID: 29922288
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemokines in host-parasite interactions in leishmaniasis.
    Teixeira MJ; Teixeira CR; Andrade BB; Barral-Netto M; Barral A
    Trends Parasitol; 2006 Jan; 22(1):32-40. PubMed ID: 16310413
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotherapy with live BCG plus heat killed Leishmania induces a T helper 1-like response in American cutaneous leishmaniasis patients.
    Cabrera M; Blackwell JM; Castes M; Trujillo D; Convit J; Shaw MA
    Parasite Immunol; 2000 Feb; 22(2):73-9. PubMed ID: 10652119
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Determinants of Innate Immunity in Visceral Leishmaniasis and Their Implication in Vaccine Development.
    Volpedo G; Pacheco-Fernandez T; Bhattacharya P; Oljuskin T; Dey R; Gannavaram S; Satoskar AR; Nakhasi HL
    Front Immunol; 2021; 12():748325. PubMed ID: 34712235
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent updates and perspectives on leishmaniasis.
    Savoia D
    J Infect Dev Ctries; 2015 Jul; 9(6):588-96. PubMed ID: 26142667
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Leishmaniasis in humans: drug or vaccine therapy?
    Ghorbani M; Farhoudi R
    Drug Des Devel Ther; 2018; 12():25-40. PubMed ID: 29317800
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vaccine candidates for leishmaniasis: a review.
    Nagill R; Kaur S
    Int Immunopharmacol; 2011 Oct; 11(10):1464-88. PubMed ID: 21616175
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunotherapy and Immunochemotherapy in Visceral Leishmaniasis: Promising Treatments for this Neglected Disease.
    Roatt BM; Aguiar-Soares RD; Coura-Vital W; Ker HG; Moreira Nd; Vitoriano-Souza J; Giunchetti RC; Carneiro CM; Reis AB
    Front Immunol; 2014; 5():272. PubMed ID: 24982655
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunomodulation by chemotherapeutic agents against Leishmaniasis.
    Saha P; Mukhopadhyay D; Chatterjee M
    Int Immunopharmacol; 2011 Nov; 11(11):1668-79. PubMed ID: 21875692
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.